Sanofi to sell 51% stake in Opella
Sanofi, CD&R in Exclusive Negotiations for Sale, Purchase of 50% Stake in Opella
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareSanofi and CD&R enter exclusive negotiations to transfer a 50% ...
When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the ...
With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...
Clayton Dubilier & Rice is working on a package of commitments amid political concerns that its purchase of a controlling ...
Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 ...
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
PAI Partners raises offer for Sanofi's consumer health unit, Opella, by €200 million and aims to keep key operations in ...
PAI partners submitted an improved bid for Sanofi's consumer health business, in an attempt to reenter the race for what could be one of the pharma industry's biggest deals this year.
The proposed sale turned into a real political issue because Opella's products include Doliprane, the best-selling medicine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback